SMT201500037B - Sali di 2,3-diidroimidazoÄ1,2-cÜchinazolina sostituiti - Google Patents

Sali di 2,3-diidroimidazoÄ1,2-cÜchinazolina sostituiti

Info

Publication number
SMT201500037B
SMT201500037B SM201500037T SM201500037T SMT201500037B SM T201500037 B SMT201500037 B SM T201500037B SM 201500037 T SM201500037 T SM 201500037T SM 201500037 T SM201500037 T SM 201500037T SM T201500037 B SMT201500037 B SM T201500037B
Authority
SM
San Marino
Prior art keywords
cüchinazoline
salts
substituted
cüchinazoline substituted
Prior art date
Application number
SM201500037T
Other languages
English (en)
Inventor
Jan Georg Peters
Hans-Christian Militzer
Hartwig Muller
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43984137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201500037(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of SMT201500037B publication Critical patent/SMT201500037B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
SM201500037T 2011-04-05 2015-02-12 Sali di 2,3-diidroimidazoÄ1,2-cÜchinazolina sostituiti SMT201500037B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11161111A EP2508525A1 (en) 2011-04-05 2011-04-05 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
PCT/EP2012/055600 WO2012136553A1 (en) 2011-04-05 2012-03-29 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Publications (1)

Publication Number Publication Date
SMT201500037B true SMT201500037B (it) 2015-05-05

Family

ID=43984137

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500037T SMT201500037B (it) 2011-04-05 2015-02-12 Sali di 2,3-diidroimidazoÄ1,2-cÜchinazolina sostituiti

Country Status (42)

Country Link
US (2) US10383876B2 (it)
EP (2) EP2508525A1 (it)
JP (2) JP5763834B2 (it)
KR (1) KR101937501B1 (it)
CN (1) CN103649091B (it)
AP (1) AP3709A (it)
AR (1) AR085718A1 (it)
AU (1) AU2012238891B2 (it)
BR (1) BR112013025549A2 (it)
CA (1) CA2832123C (it)
CL (1) CL2013002870A1 (it)
CO (1) CO6781534A2 (it)
CR (1) CR20130511A (it)
CU (1) CU24208B1 (it)
CY (1) CY1116231T1 (it)
DK (1) DK2694508T3 (it)
DO (1) DOP2013000223A (it)
EA (1) EA023646B1 (it)
EC (1) ECSP13013006A (it)
ES (1) ES2529653T3 (it)
GT (1) GT201300234A (it)
HK (1) HK1195907A1 (it)
HR (1) HRP20150138T1 (it)
IL (1) IL228561A (it)
JO (1) JO2958B1 (it)
MA (1) MA35014B1 (it)
ME (1) ME02021B (it)
MX (1) MX336057B (it)
MY (1) MY169452A (it)
PE (1) PE20141038A1 (it)
PL (1) PL2694508T3 (it)
PT (1) PT2694508E (it)
RS (1) RS53811B1 (it)
SG (1) SG193595A1 (it)
SI (1) SI2694508T1 (it)
SM (1) SMT201500037B (it)
TN (1) TN2013000401A1 (it)
TW (2) TWI549954B (it)
UA (1) UA111604C2 (it)
UY (1) UY33985A (it)
WO (1) WO2012136553A1 (it)
ZA (1) ZA201307105B (it)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EA037577B1 (ru) 2013-04-08 2021-04-16 Байер Фарма Акциенгезельшафт ПРИМЕНЕНИЕ 2-АМИНО-N-[7-МЕТОКСИ-8-(3-МОРФОЛИН-4-ИЛПРОПОКСИ)-2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИН-5-ИЛ]ПИРИМИДИН-5-КАРБОКСАМИДА ИЛИ ЕГО ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ИЛИ ГИДРАТА И ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ УКАЗАННОЕ СОЕДИНЕНИЕ, ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ НЕХОДЖКИНСКОЙ ЛИМФОМЫ (НХЛ)
JP2016521715A (ja) 2013-06-14 2016-07-25 バイエル ファーマ アクチエンゲゼルシャフト 抗tweakr抗体およびその使用
CN103694319B (zh) * 2013-12-20 2018-02-27 深圳翰宇药业股份有限公司 一种布舍瑞林的纯化方法
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
KR20180013851A (ko) * 2015-03-09 2018-02-07 바이엘 파마 악티엔게젤샤프트 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물
AU2016231260A1 (en) * 2015-03-09 2017-09-21 Bayer Healthcare Pharmaceuticals Inc. Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
PE20171790A1 (es) 2015-03-23 2017-12-28 Bayer Pharma AG Anticuerpos anti-ceacam6 y sus usos
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
KR20180101603A (ko) 2016-02-01 2018-09-12 바이엘 파마 악티엔게젤샤프트 코판리십 바이오마커
EP3411498A1 (en) 2016-02-01 2018-12-12 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
TWI825834B (zh) 2016-03-02 2023-12-11 日商衛材R&D企管股份有限公司 基於艾日布林之抗體-藥物結合物及使用方法
US10844066B2 (en) 2016-03-08 2020-11-24 Bayer Pharma Aktiengesellschaft 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
US10925880B2 (en) 2016-09-23 2021-02-23 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
JP2020503289A (ja) 2016-12-14 2020-01-30 ターベダ セラピューティクス インコーポレイテッドTarveda Therapeutics,Inc. Hsp90標的化コンジュゲート及びその製剤
EP3585437B1 (en) 2017-02-24 2022-12-21 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
MA50068A (fr) 2017-09-08 2021-06-02 Bayer Consumer Care Ag Formulations de copanlisib
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
CA3116230A1 (en) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
AU2019360377A1 (en) * 2018-10-17 2021-04-29 Sandoz Ag Co-crystals comprising levothyroxine and a dicarboxylic acid
US20220064171A1 (en) * 2018-12-27 2022-03-03 Holosmedic Novel compound and pharmaceutical composition comprising same for enhancing anticancer activity
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH605550A5 (it) 1972-06-08 1978-09-29 Research Corp
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (it) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
ES2367141T3 (es) 2002-09-30 2011-10-28 Bayer Pharma Aktiengesellschaft Derivados de azol-pirimidina condensados.
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2244721A4 (en) * 2008-01-14 2017-01-18 Bayer Intellectual Property GmbH Sulfone substituted 2,3-dihydroimidazo ý1,2-c¨quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2168582A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
CN102958540B (zh) 2010-04-16 2015-09-02 拜耳知识产权有限责任公司 含取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EA037577B1 (ru) 2013-04-08 2021-04-16 Байер Фарма Акциенгезельшафт ПРИМЕНЕНИЕ 2-АМИНО-N-[7-МЕТОКСИ-8-(3-МОРФОЛИН-4-ИЛПРОПОКСИ)-2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИН-5-ИЛ]ПИРИМИДИН-5-КАРБОКСАМИДА ИЛИ ЕГО ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ИЛИ ГИДРАТА И ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ УКАЗАННОЕ СОЕДИНЕНИЕ, ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ НЕХОДЖКИНСКОЙ ЛИМФОМЫ (НХЛ)
US10117874B2 (en) 2013-12-03 2018-11-06 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
KR20180013851A (ko) 2015-03-09 2018-02-07 바이엘 파마 악티엔게젤샤프트 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물
AU2016231260A1 (en) * 2015-03-09 2017-09-21 Bayer Healthcare Pharmaceuticals Inc. Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines

Also Published As

Publication number Publication date
CN103649091B (zh) 2016-06-22
MX2013011583A (es) 2013-12-16
MX336057B (es) 2016-01-07
RS53811B1 (en) 2015-06-30
CR20130511A (es) 2013-12-04
IL228561A (en) 2015-10-29
UY33985A (es) 2012-10-31
GT201300234A (es) 2015-01-16
CN103649091A (zh) 2014-03-19
CY1116231T1 (el) 2017-02-08
CA2832123A1 (en) 2012-10-11
JP2014510119A (ja) 2014-04-24
JO2958B1 (en) 2016-03-15
BR112013025549A2 (pt) 2016-12-27
HK1195907A1 (zh) 2014-11-28
JP2015164936A (ja) 2015-09-17
AR085718A1 (es) 2013-10-23
KR20140021637A (ko) 2014-02-20
US10383876B2 (en) 2019-08-20
AU2012238891A1 (en) 2013-10-24
ECSP13013006A (es) 2013-12-31
PE20141038A1 (es) 2014-09-05
ZA201307105B (en) 2014-11-26
PT2694508E (pt) 2015-02-10
TWI549954B (zh) 2016-09-21
EP2694508B1 (en) 2014-11-19
US20160193219A1 (en) 2016-07-07
CO6781534A2 (es) 2013-10-31
WO2012136553A1 (en) 2012-10-11
IL228561A0 (en) 2013-12-31
UA111604C2 (uk) 2016-05-25
EA023646B1 (ru) 2016-06-30
TWI592158B (zh) 2017-07-21
TN2013000401A1 (en) 2015-03-30
JP5826961B2 (ja) 2015-12-02
MA35014B1 (fr) 2014-04-03
CL2013002870A1 (es) 2014-06-20
DK2694508T3 (en) 2015-02-16
DOP2013000223A (es) 2013-11-15
AP2013007219A0 (en) 2013-10-31
ME02021B (me) 2015-05-20
EP2694508A1 (en) 2014-02-12
EP2508525A1 (en) 2012-10-10
KR101937501B1 (ko) 2019-01-10
AU2012238891B2 (en) 2016-12-01
AP3709A (en) 2016-05-31
CA2832123C (en) 2018-09-11
JP5763834B2 (ja) 2015-08-12
EA201391470A1 (ru) 2014-03-31
ES2529653T3 (es) 2015-02-24
US20140072529A1 (en) 2014-03-13
TW201637656A (zh) 2016-11-01
TW201249847A (en) 2012-12-16
US9636344B2 (en) 2017-05-02
MY169452A (en) 2019-04-11
NZ616198A (en) 2015-09-25
CU20130133A7 (es) 2014-01-29
SG193595A1 (en) 2013-10-30
SI2694508T1 (sl) 2015-03-31
PL2694508T3 (pl) 2015-04-30
HRP20150138T1 (hr) 2015-05-08
CU24208B1 (es) 2016-11-29

Similar Documents

Publication Publication Date Title
SMT201500037B (it) Sali di 2,3-diidroimidazoÄ1,2-cÜchinazolina sostituiti
SMT201700111B (it) Eterociclilammine come inibitori di pi3k
SMT201600328B (it) Nuovi composti come inibitori di diacilglicerolo aciltransferasi
CO6900145A2 (es) Compuesto de ciclopropanoamina
CO6890099A2 (es) Nuevos derivados dihidroquinolina-2-ona
IT1403931B1 (it) Miscela di sali nitrati inorganici.
BR112014000284A2 (pt) composição fotoprotetora
BR112014012016A2 (pt) compostos
DK2678329T3 (da) Triazolopyridinforbindelser som pim-kinase-hæmmere
CO6910197A2 (es) Compuestos novedosos
DK2734499T3 (da) Merocyanine derivatives
DK2734740T3 (da) Skruehoved
SMT201600425B (it) Preparazione per colonscopia
CO6811866A2 (es) Derivados de benzamida sustituida
BR112013028029A2 (pt) composto
CO6842023A2 (es) Composición herbicida
DE112011105163T8 (de) Wirbelströmungserzeuger
IT1404486B1 (it) Macchina seminatrice semovente di piccole dimensioni
BR112014008091A2 (pt) escova de dentes
FR2975564B1 (fr) Charrue
DK2532220T3 (da) Marksprøjte
DE102012004638A8 (de) Armkopf
BR112013032213A2 (pt) cocho independente
BR302012001925S1 (pt) "configuração aplicada em calota"
BR112014015607A2 (pt) composto